DHIRAJ KUMAR YADAV M.D.
Prescription History 1104267608
Internal Medicine - Hematology & Oncology in Wailuku, HI

NPI Status: Active since July 12, 2013

Contact Information

85 MAUI LANI PKWY
WAILUKU, HI
ZIP 96793
Phone: (808) 442-5700
Fax: (855) 827-2321

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DHIRAJ KUMAR YADAV M.D., an active Hematology & Oncology specialist practicing in Wailuku, HI. Our medical registry currently tracks 27 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 648 documented patient claims. Among these therapy options, the most frequently utilized medication is Acyclovir, which accounts for 61 claims alone.


Abiraterone Acetate

Generic Formulation: Abiraterone AcetateSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 40
30-Day Fills 40.0
Days Supply 1,200
HI State Average Benchmarks
Peer Average Claims37.0
Peer Average 30-Day Fills37.7
Peer Average Days Supply1,126
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across HI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $218,611.49 across this reporting matrix range.

Provider Avg Cost Per Claim

$5,465.29

State Avg Cost Per Claim

$2,307.46

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An androstene derivative that inhibits STEROID 17-ALPHA-HYDROXYLASE and is used as an ANTINEOPLASTIC AGENT in the treatment of metastatic castration-resistant PROSTATE CANCER.

Therapeutic Applications

This medication is used to treat prostate cancer. Abiraterone belongs to a class of drugs known as anti-androgens (anti-testosterone). Testosterone, a natural hormone, helps prostate cancer to grow and spread. Abiraterone works by blocking the production of testosterone, thereby slowing the growth and spread of prostate cancer. This medication should not be given to women or children.

Acyclovir

Generic Formulation: AcyclovirSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 61
30-Day Fills 75.0
Days Supply 2,212
HI State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills39.6
Peer Average Days Supply1,000
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 177.3% higher than the standard regional baseline profile for HI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $920.86 across this reporting matrix range.

Provider Avg Cost Per Claim

$15.10

State Avg Cost Per Claim

$27.89

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.

Therapeutic Applications

Acyclovir is used to treat infections caused by certain types of viruses. It treats cold sores around the mouth (caused by herpes simplex), shingles (caused by herpes zoster), and chickenpox. This medication is also used to treat outbreaks of genital herpes. In people with frequent outbreaks, acyclovir is used to help reduce the number of future episodes. Acyclovir is an antiviral drug. However, it is not a cure for these infections. The viruses that cause these infections continue to live in the body even between outbreaks. Acyclovir decreases the severity and length of these outbreaks. It helps the sores heal faster, keeps new sores from forming, and decreases pain/itching. This medication may also help reduce how long pain remains after the sores heal. In addition, in people with a weakened immune system, acyclovir can decrease the risk of the virus spreading to other parts of the body and causing serious infections.

Allopurinol

Generic Formulation: AllopurinolSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 12
30-Day Fills 14.0
Days Supply 420
HI State Average Benchmarks
Peer Average Claims60.0
Peer Average 30-Day Fills165.6
Peer Average Days Supply4,959
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 80.0% less volume than the regional standard for practitioners inside HI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $108.33 across this reporting matrix range.

Provider Avg Cost Per Claim

$9.03

State Avg Cost Per Claim

$16.62

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms.

Therapeutic Applications

Allopurinol is used to treat gout and certain types of kidney stones. It is also used to prevent increased uric acid levels in patients receiving cancer chemotherapy. These patients can have increased uric acid levels due to release of uric acid from the dying cancer cells. Allopurinol works by reducing the amount of uric acid made by the body. Increased uric acid levels can cause gout and kidney problems.

Anastrozole

Generic Formulation: AnastrozoleSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 20
30-Day Fills 44.0
Days Supply 1,320
HI State Average Benchmarks
Peer Average Claims69.0
Peer Average 30-Day Fills182.4
Peer Average Days Supply5,462
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 71.0% less volume than the regional standard for practitioners inside HI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $285.90 across this reporting matrix range.

Provider Avg Cost Per Claim

$14.30

State Avg Cost Per Claim

$25.07

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nitrile and triazole derivative that acts as a selective nonsteroidal aromatase inhibitor. It is used in the treatment of ESTROGEN NUCLEAR RECEPTOR-positive breast cancer in postmenopausal women.

Therapeutic Applications

Anastrozole is used to treat breast cancer in women after menopause. Some breast cancers are made to grow faster by a natural hormone called estrogen. Anastrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Calquence

Generic Formulation: Acalabrutinib MaleateSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 390
HI State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills23.3
Peer Average Days Supply700
Conservative Utilization

This provider writes prescriptions for this formulation 43.5% less frequently than the standard regional baseline metric for practitioners inside HI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $155,640.96 across this reporting matrix range.

Provider Avg Cost Per Claim

$11,972.38

State Avg Cost Per Claim

$13,484.92

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of cancer (such as mantle cell lymphoma, small lymphocytic lymphoma - SLL, chronic lymphocytic leukemia - CLL). Acalabrutinib works by slowing or stopping the growth of cancer cells. It belongs to a class of drugs known as kinase inhibitors.

Dexamethasone

Generic Formulation: DexamethasoneSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 35
30-Day Fills 35.4
Days Supply 785
HI State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills35.6
Peer Average Days Supply523
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across HI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $401.75 across this reporting matrix range.

Provider Avg Cost Per Claim

$11.48

State Avg Cost Per Claim

$18.27

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An anti-inflammatory 9-fluoro-glucocorticoid.

Therapeutic Applications

Dexamethasone is used to treat conditions such as arthritis, blood/hormone disorders, allergic reactions, skin diseases, eye problems, breathing problems, bowel disorders, cancer, and immune system disorders. It is also used as a test for an adrenal gland disorder (Cushing's syndrome). Dexamethasone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Eliquis

Generic Formulation: ApixabanSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 21
30-Day Fills 36.0
Days Supply 1,072
HI State Average Benchmarks
Peer Average Claims48.0
Peer Average 30-Day Fills94.8
Peer Average Days Supply2,805
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 56.3% less volume than the regional standard for practitioners inside HI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $20,851.19 across this reporting matrix range.

Provider Avg Cost Per Claim

$992.91

State Avg Cost Per Claim

$1,025.42

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Apixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/knee replacement surgery. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to blood clots forming, which can travel to other parts of your body (such as the lungs or legs) or increase your risk for stroke. In the United States, apixaban is also approved to treat certain types of blood clots (deep vein thrombosis-DVT, pulmonary embolus-PE) and to prevent them from forming again. Apixaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Hydroxyurea

Generic Formulation: HydroxyureaSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 42
30-Day Fills 102.3
Days Supply 3,069
HI State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills71.8
Peer Average Days Supply2,136
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 31.3% more claims than the standard regional baseline profile for HI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,518.68 across this reporting matrix range.

Provider Avg Cost Per Claim

$36.16

State Avg Cost Per Claim

$39.74

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.

Therapeutic Applications

This medication is used by people with sickle cell anemia to reduce the number of painful crises caused by the disease and to reduce the need for blood transfusions. Some brands are also used to treat certain types of cancer (such as chronic myelogenous leukemia, squamous cell carcinomas).

Imatinib Mesylate

Generic Formulation: Imatinib MesylateSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 390
HI State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills27.3
Peer Average Days Supply815
Conservative Utilization

This provider writes prescriptions for this formulation 48.0% less frequently than the standard regional baseline metric for practitioners inside HI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $60,570.62 across this reporting matrix range.

Provider Avg Cost Per Claim

$4,659.28

State Avg Cost Per Claim

$1,981.19

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors.

Therapeutic Applications

This medication is used to treat certain types of cancer (such as acute lymphoblastic leukemia, chronic myeloid leukemia, gastrointestinal stromal tumors, and myelodysplastic/myeloproliferative diseases). It works by slowing or stopping the growth of cancer cells. Imatinib may also be used to treat certain immune system disorders (such as aggressive systemic mastocytosis, hypereosinophilic syndrome).

Jakafi

Generic Formulation: Ruxolitinib PhosphateSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
HI State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills21.1
Peer Average Days Supply629
Conservative Utilization

This provider writes prescriptions for this formulation 45.0% less frequently than the standard regional baseline metric for practitioners inside HI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $180,229.60 across this reporting matrix range.

Provider Avg Cost Per Claim

$16,384.51

State Avg Cost Per Claim

$14,305.37

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain bone marrow disorders (myelofibrosis, polycythemia vera). It works by blocking your body from producing substances called growth factors. Growth factors cause cells to grow and divide, and cause the blood cell and spleen problems found in these disorders. Ruxolitinib belongs to a class of drugs known as kinase inhibitors. Though not a cure for these disorders, ruxolitinib may help with some of the symptoms, including abdominal discomfort, pain under left ribs, early feelings of fullness from meals, night sweats, itching, and bone/muscle pain. Ruxolitinib is also used to treat a certain problem that may occur after certain stem cell or bone marrow transplants (graft versus host disease). It works by weakening your body's defense system (immune system).

Lenvima

Generic Formulation: Lenvatinib MesylateSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 315
HI State Average Benchmarks
Peer Average Claims14.0
Peer Average 30-Day Fills14.0
Peer Average Days Supply415
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across HI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $221,808.24 across this reporting matrix range.

Provider Avg Cost Per Claim

$20,164.39

State Avg Cost Per Claim

$20,491.05

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat cancer. Lenvatinib belongs to a class of drugs known as tyrosine kinase inhibitors. It works by slowing or stopping the growth of cancer cells.

Letrozole

Generic Formulation: LetrozoleSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 21
30-Day Fills 31.0
Days Supply 930
HI State Average Benchmarks
Peer Average Claims40.0
Peer Average 30-Day Fills100.3
Peer Average Days Supply3,008
Conservative Utilization

This provider writes prescriptions for this formulation 47.5% less frequently than the standard regional baseline metric for practitioners inside HI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $333.07 across this reporting matrix range.

Provider Avg Cost Per Claim

$15.86

State Avg Cost Per Claim

$19.03

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A triazole and benzonitrile derivative that is a selective non-steroidal aromatase inhibitor, similar to ANASTROZOLE. It is used in the treatment of metastatic or locally advanced breast cancer in postmenopausal women.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Letrozole is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Letrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Levothyroxine Sodium

Generic Formulation: Levothyroxine SodiumSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 28
30-Day Fills 44.3
Days Supply 1,330
HI State Average Benchmarks
Peer Average Claims92.0
Peer Average 30-Day Fills246.8
Peer Average Days Supply7,367
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 69.6% less volume than the regional standard for practitioners inside HI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $292.01 across this reporting matrix range.

Provider Avg Cost Per Claim

$10.43

State Avg Cost Per Claim

$20.16

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.

Therapeutic Applications

Levothyroxine is used to treat an underactive thyroid (hypothyroidism). It replaces or provides more thyroid hormone, which is normally produced by the thyroid gland. Low thyroid hormone levels can occur naturally or when the thyroid gland is injured by radiation/medications or removed by surgery. Having enough thyroid hormone is important for maintaining normal mental and physical activity. In children, having enough thyroid hormone is important for normal mental and physical development. This medication is also used to treat other types of thyroid disorders (such as thyroid cancer). This medication should not be used to treat infertility unless it is caused by low thyroid hormone levels.

Lidocaine-Prilocaine

Generic Formulation: Lidocaine/PrilocaineSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 265
HI State Average Benchmarks
Peer Average Claims16.0
Peer Average 30-Day Fills16.5
Peer Average Days Supply408
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across HI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $257.16 across this reporting matrix range.

Provider Avg Cost Per Claim

$19.78

State Avg Cost Per Claim

$24.30

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A topical local anesthetic preparation that is composed of a mixture of lidocaine and prilocaine. It is used to provide anesthesia during minor surgery and for the treatment of PREMATURE EJACULATION.

Therapeutic Applications

This medication contains 2 amide-type local anesthetics, lidocaine and prilocaine. It is used on normal, unbroken skin or on the outer genital area to prevent pain before certain procedures such as inserting a needle, skin grafts, or skin laser surgery. It works by temporarily numbing the skin and surrounding area. Do not use this product in the ears. If this product alone cannot completely numb the area being treated, it may be used to numb the area before a lidocaine injection is given to provide enough pain relief for certain procedures (such as removal of genital warts).

Ondansetron Hcl

Generic Formulation: Ondansetron HclSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 25
30-Day Fills 25.0
Days Supply 247
HI State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills23.4
Peer Average Days Supply280
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across HI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $237.86 across this reporting matrix range.

Provider Avg Cost Per Claim

$9.51

State Avg Cost Per Claim

$21.36

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used alone or with other medications to prevent nausea and vomiting caused by cancer drug treatment (chemotherapy) and radiation therapy. It is also used to prevent and treat nausea and vomiting after surgery. It works by blocking one of the body's natural substances (serotonin) that causes vomiting.

Ondansetron Odt

Generic Formulation: OndansetronSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 27
30-Day Fills 27.0
Days Supply 313
HI State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills20.1
Peer Average Days Supply193
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 42.1% more claims than the standard regional baseline profile for HI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $858.47 across this reporting matrix range.

Provider Avg Cost Per Claim

$31.80

State Avg Cost Per Claim

$24.86

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.

Therapeutic Applications

This medication is used alone or with other medications to prevent nausea and vomiting caused by cancer drug treatment (chemotherapy) and radiation therapy. It is also used to prevent and treat nausea and vomiting after surgery. Ondansetron works by blocking one of the body's natural substances (serotonin) that causes vomiting.

Potassium Chloride

Generic Formulation: Potassium ChlorideSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 16
30-Day Fills 18.0
Days Supply 540
HI State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills66.6
Peer Average Days Supply1,957
Conservative Utilization

This provider writes prescriptions for this formulation 48.4% less frequently than the standard regional baseline metric for practitioners inside HI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $396.27 across this reporting matrix range.

Provider Avg Cost Per Claim

$24.77

State Avg Cost Per Claim

$39.32

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A white crystal or crystalline powder used in BUFFERS; FERTILIZERS; and EXPLOSIVES. It can be used to replenish ELECTROLYTES and restore WATER-ELECTROLYTE BALANCE in treating HYPOKALEMIA.

Therapeutic Applications

This medication is a mineral supplement used to treat or prevent low amounts of potassium in the blood. A normal level of potassium in the blood is important. Potassium helps your cells, kidneys, heart, muscles, and nerves work properly. Most people get enough potassium by eating a well-balanced diet. Some conditions that can lower your body's potassium level include severe prolonged diarrhea and vomiting, hormone problems such as hyperaldosteronism, or treatment with water pills/diuretics.

Prednisone

Generic Formulation: PrednisoneSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 45
30-Day Fills 47.0
Days Supply 988
HI State Average Benchmarks
Peer Average Claims41.0
Peer Average 30-Day Fills53.9
Peer Average Days Supply1,046
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across HI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $202.45 across this reporting matrix range.

Provider Avg Cost Per Claim

$4.50

State Avg Cost Per Claim

$6.53

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Therapeutic Applications

Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Prochlorperazine Maleate

Generic Formulation: Prochlorperazine MaleateSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 39
30-Day Fills 39.0
Days Supply 313
HI State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills25.6
Peer Average Days Supply279
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 56.0% higher than the standard regional baseline profile for HI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $561.87 across this reporting matrix range.

Provider Avg Cost Per Claim

$14.41

State Avg Cost Per Claim

$16.16

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phenothiazine antipsychotic used principally in the treatment of NAUSEA; VOMITING; and VERTIGO. It is more likely than CHLORPROMAZINE to cause EXTRAPYRAMIDAL DISORDERS. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612)

Therapeutic Applications

This medication is used to treat severe nausea and vomiting from certain causes (for example, after surgery or cancer treatment). Prochlorperazine belongs to a class of drugs known as phenothiazines. This medication is not recommended for use in children younger than 2 years or in children going through surgery.

Revlimid

Generic Formulation: LenalidomideSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 30
30-Day Fills 30.0
Days Supply 833
HI State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills28.6
Peer Average Days Supply761
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across HI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $579,645.18 across this reporting matrix range.

Provider Avg Cost Per Claim

$19,321.51

State Avg Cost Per Claim

$17,948.11

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phthalimide and piperidone derivative that has immunomodulatory and antiangiogenic properties. It is used for the treatment of transfusion-dependent anemia in MYELODYSPLASTIC SYNDROMES, and for the treatment of MULTIPLE MYELOMA, and relapsed or refractory MANTLE CELL LYMPHOMA.

Therapeutic Applications

Lenalidomide is used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders (myelodysplastic syndromes-MDS). Lenalidomide may lessen the need for blood transfusions. Lenalidomide is not recommended for the treatment of a certain type of cancer (chronic lymphocytic leukemia) because of the increased risk of serious heart-related side effects and death. If you have this type of cancer, talk to your doctor about the risks of using this medication.

Sulfamethoxazole-Trimethoprim

Generic Formulation: Sulfamethoxazole/TrimethoprimSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 25
30-Day Fills 37.9
Days Supply 1,074
HI State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills25.6
Peer Average Days Supply337
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across HI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $220.68 across this reporting matrix range.

Provider Avg Cost Per Claim

$8.83

State Avg Cost Per Claim

$5.82

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A drug combination with broad-spectrum antibacterial activity against both gram-positive and gram-negative organisms. It is effective in the treatment of many infections, including PNEUMOCYSTIS PNEUMONIA in AIDS.

Therapeutic Applications

This medication is a combination of two antibiotics: sulfamethoxazole and trimethoprim. It is used to treat a wide variety of bacterial infections (such as middle ear, urine, respiratory, and intestinal infections). It is also used to prevent and treat a certain type of pneumonia (pneumocystis-type). This medication should not be used by children less than 2 months of age due to the risk of serious side effects. This medication treats only certain types of infections. It will not work for viral infections (such as flu). Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Tagrisso

Generic Formulation: Osimertinib MesylateSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 16
30-Day Fills 16.0
Days Supply 480
HI State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills29.6
Peer Average Days Supply887
Conservative Utilization

This provider writes prescriptions for this formulation 44.8% less frequently than the standard regional baseline metric for practitioners inside HI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $263,718.84 across this reporting matrix range.

Provider Avg Cost Per Claim

$16,482.43

State Avg Cost Per Claim

$16,785.61

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat lung cancer. Osimertinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells. It binds to a certain protein (epidermal growth factor receptor-EGFR) in some tumors.

Tamoxifen Citrate

Generic Formulation: Tamoxifen CitrateSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 18
30-Day Fills 22.0
Days Supply 660
HI State Average Benchmarks
Peer Average Claims41.0
Peer Average 30-Day Fills110.3
Peer Average Days Supply3,300
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 56.1% less volume than the regional standard for practitioners inside HI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $393.82 across this reporting matrix range.

Provider Avg Cost Per Claim

$21.88

State Avg Cost Per Claim

$34.75

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.

Therapeutic Applications

Tamoxifen is used to treat breast cancer. It is also used to reduce the chances of breast cancer in high-risk patients. This medication can block the growth of breast cancer. It works by interfering with the effects of estrogen in the breast tissue.

Tramadol Hcl

Generic Formulation: Tramadol HclSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 168
HI State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills34.3
Peer Average Days Supply643
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 60.6% less volume than the regional standard for practitioners inside HI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $64.18 across this reporting matrix range.

Provider Avg Cost Per Claim

$4.94

State Avg Cost Per Claim

$7.70

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A narcotic analgesic proposed for severe pain. It may be habituating.

Therapeutic Applications

See also Warning section. This medication is used to help relieve moderate to moderately severe pain. Tramadol belongs to a class of drugs known as opioid analgesics. It works in the brain to change how your body feels and responds to pain.

Verzenio

Generic Formulation: AbemaciclibSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 15
30-Day Fills 15.0
Days Supply 420
HI State Average Benchmarks
Peer Average Claims15.0
Peer Average 30-Day Fills15.8
Peer Average Days Supply443
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across HI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $241,152.18 across this reporting matrix range.

Provider Avg Cost Per Claim

$16,076.81

State Avg Cost Per Claim

$14,251.61

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of breast cancer. Abemaciclib works by slowing or stopping the growth of cancer cells. It belongs to a class of drugs known as kinase inhibitors.

Xarelto

Generic Formulation: RivaroxabanSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 420
HI State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills71.2
Peer Average Days Supply2,110
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 56.3% less volume than the regional standard for practitioners inside HI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $8,073.09 across this reporting matrix range.

Provider Avg Cost Per Claim

$576.65

State Avg Cost Per Claim

$1,094.15

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.

Therapeutic Applications

Rivaroxaban is used to prevent blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip or knee replacement surgery. It is also used to prevent blood clots from forming in high-risk patients with limited mobility during their hospital stay and after discharge. In addition, rivaroxaban is used to treat blood clots (such as in deep vein thrombosis-DVT or pulmonary embolus-PE) and to prevent the blood clots from forming again. Rivaroxaban may be used in children to prevent blood clots from forming after a certain heart surgery (Fontan procedure). Rivaroxaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Xtandi

Generic Formulation: EnzalutamideSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 24
30-Day Fills 24.0
Days Supply 720
HI State Average Benchmarks
Peer Average Claims35.0
Peer Average 30-Day Fills35.8
Peer Average Days Supply1,072
Conservative Utilization

This provider writes prescriptions for this formulation 31.4% less frequently than the standard regional baseline metric for practitioners inside HI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $299,379.60 across this reporting matrix range.

Provider Avg Cost Per Claim

$12,474.15

State Avg Cost Per Claim

$11,728.70

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Enzalutamide is used to treat prostate cancer. This medication belongs to a class of drugs known as anti-androgens (anti-testosterone). It works by blocking the effects of testosterone to slow the growth and spread of prostate cancer.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DHIRAJ KUMAR YADAV M.D. provides transparency into local medical care patterns within Wailuku, HI.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Hematology & Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.